Production (Stage)
AstraZeneca PLC
AZN
$70.41
$0.460.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -8.75% | 9.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.75% | 9.78% | |||
| Cost of Revenue | -20.56% | 14.18% | |||
| Gross Profit | -6.00% | 8.80% | |||
| SG&A Expenses | -11.32% | 8.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -185.00% | -60.00% | |||
| Total Operating Expenses | -14.91% | 12.27% | |||
| Operating Income | 12.21% | 2.05% | |||
| Income Before Tax | 104.20% | -8.86% | |||
| Income Tax Expenses | 189.76% | -57.97% | |||
| Earnings from Continuing Operations | 94.73% | 4.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | 100.00% | |||
| Net Income | 94.40% | 4.97% | |||
| EBIT | 12.21% | 2.05% | |||
| EBITDA | 21.10% | -9.45% | |||
| EPS Basic | 94.41% | 4.97% | |||
| Normalized Basic EPS | 14.78% | 1.07% | |||
| EPS Diluted | 94.21% | 5.81% | |||
| Normalized Diluted EPS | 14.87% | 1.07% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | -0.06% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 572.90% | -1.00% | |||